Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 202

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 202
---
ated articles of association, which requires the prior approval of the holders of a majority of the voting power
attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate
and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as
described above in “—Voting Rights.”

Borrowing Powers

Pursuant to the Companies
Law and our amended and restated articles of association to be in effect upon completion of this offering, our board of directors may
exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to
be exercised or taken by our shareholders, including the power to borrow money for company purposes.

Changes in Capital

Our amended and restated
articles of association to be in effect upon completion of this offering enable us to increase or reduce our share capital. Any such
change is subject to Israeli law and must be approved by a resolution duly passed by our shareholders at a general meeting. In addition,
transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient
retained earnings or profits, may require the approval of both our board of directors and an Israeli court.

Transfer Agent and Registrar

The transfer agent and registrar
for our Ordinary Shares is . Its address is ,
and its telephone number is .

Listing

We have applied to have our
Ordinary Shares listed on the Nasdaq Capital Market under the symbol “RGNT”. No assurance can be given that our application
will be approved or that a trading market will develop.

<div align='center'>123

DESCRIPTION OF THE SECURITIES WE ARE OFFERING</div>

Ordinary Shares

The material terms and provisions
of our Ordinary Shares are described under the caption “Description of Share Capital” in this prospectus.

<div align='center'>SHARES ELIGIBLE FOR FUTURE SALE</div>

Prior to this offering, no
public market existed for our Ordinary Shares. Sales of substantial amounts of our Ordinary Shares following this offering, or the perception
that these sales could occur, could adversely affect prevailing market prices of our Ordinary Shares and could impair our future ability
to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise in full their
option to purchase additional Ordinary Shares and/or additional Warrants with respect to this offering and assuming no exercise of options
outstanding